MedTrace Logo

The Impact of Brief Behavioral Treatment for Insomnia Versus Brief Mindfulness Treatment on Cognition and Sleep Health in Adults (Age 50+) With HIV

NCT07272863 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 214

Last updated 2026-05-08

No results posted yet for this study

Summary

The goal of this clinical trial is to examine the effects of a telephone-delivered Brief Behavioral Treatment Insomnia (BBTI) versus a Brief Mindfulness Treatment (BMT) on cognitive and sleep outcomes in older adults with HIV. The main questions it aims to answer are:

What are the effects of BBTI vs BMT on self-reported and observed sleep outcomes in older adults with HIV and insomnia up to 1-year post-intervention? What are the effects of BBTI vs BMT on self-reported and observed cognitive comes in older adults with HIV and insomnia up to 1-year post-intervention? What is the association between Alzheimer's Disease biomarkers and sleep and cognitive outcomes in older adults with HIV receiving BBTI vs BMT?

Participants will:

* Complete 4 weeks of telephone-delivered BBTI or BMT
* Attend baseline, post-intervention, and 1-year post in-person visits for sleep and cognitive assessments
* Have blood collected at all three time points

Conditions

Interventions

BEHAVIORAL

BBTI

4-week intervention delivered via telephone (once a week for 30 minutes)

BEHAVIORAL

BMT

4-week intervention delivered via telephone (once a week for 30 minutes)

Sponsors & Collaborators

  • University of Alabama at Birmingham

    collaborator OTHER

  • National Institute on Aging (NIA)

    collaborator NIH

  • NIH Office of AIDS Research (OAR)

    collaborator NIH

  • University of Alabama, Tuscaloosa

    lead OTHER

Principal Investigators

  • Dr. Shameka L Cody, PhD, AGNP-C, PMHNP-BC, FAAN · The University of Alabama Capstone College of Nursing

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-31
Primary Completion
2030-09-30
Completion
2030-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07272863 on ClinicalTrials.gov